ASND
Price
$172.22
Change
-$0.73 (-0.42%)
Updated
Jun 27 closing price
Capitalization
10.42B
71 days until earnings call
LSTA
Price
$2.80
Change
-$0.14 (-4.76%)
Updated
Jun 27 closing price
Capitalization
24.07M
49 days until earnings call
Interact to see
Advertisement

ASND vs LSTA

Header iconASND vs LSTA Comparison
Open Charts ASND vs LSTABanner chart's image
Ascendis Pharma A/S
Price$172.22
Change-$0.73 (-0.42%)
Volume$255.34K
Capitalization10.42B
Lisata Therapeutics
Price$2.80
Change-$0.14 (-4.76%)
Volume$42.13K
Capitalization24.07M
ASND vs LSTA Comparison Chart in %
Loading...
ASND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LSTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ASND vs. LSTA commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASND is a Buy and LSTA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (ASND: $172.22 vs. LSTA: $2.80)
Brand notoriety: ASND and LSTA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ASND: 57% vs. LSTA: 294%
Market capitalization -- ASND: $10.42B vs. LSTA: $24.07M
ASND [@Biotechnology] is valued at $10.42B. LSTA’s [@Biotechnology] market capitalization is $24.07M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ASND’s FA Score shows that 0 FA rating(s) are green whileLSTA’s FA Score has 1 green FA rating(s).

  • ASND’s FA Score: 0 green, 5 red.
  • LSTA’s FA Score: 1 green, 4 red.
According to our system of comparison, LSTA is a better buy in the long-term than ASND.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ASND’s TA Score shows that 4 TA indicator(s) are bullish while LSTA’s TA Score has 5 bullish TA indicator(s).

  • ASND’s TA Score: 4 bullish, 5 bearish.
  • LSTA’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, LSTA is a better buy in the short-term than ASND.

Price Growth

ASND (@Biotechnology) experienced а -2.65% price change this week, while LSTA (@Biotechnology) price change was +12.90% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

ASND is expected to report earnings on Sep 09, 2025.

LSTA is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ASND($10.4B) has a higher market cap than LSTA($24.1M). ASND YTD gains are higher at: 25.096 vs. LSTA (-6.040). LSTA has higher annual earnings (EBITDA): -21.48M vs. ASND (-287.37M). ASND has more cash in the bank: 518M vs. LSTA (25.8M). LSTA has less debt than ASND: LSTA (92K) vs ASND (847M). ASND has higher revenues than LSTA: ASND (369M) vs LSTA (1M).
ASNDLSTAASND / LSTA
Capitalization10.4B24.1M43,154%
EBITDA-287.37M-21.48M1,338%
Gain YTD25.096-6.040-415%
P/E RatioN/AN/A-
Revenue369M1M36,900%
Total Cash518M25.8M2,008%
Total Debt847M92K920,652%
FUNDAMENTALS RATINGS
ASND vs LSTA: Fundamental Ratings
ASND
LSTA
OUTLOOK RATING
1..100
5011
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
24
Undervalued
PROFIT vs RISK RATING
1..100
78100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
4453
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LSTA's Valuation (24) in the null industry is significantly better than the same rating for ASND (90) in the Biotechnology industry. This means that LSTA’s stock grew significantly faster than ASND’s over the last 12 months.

ASND's Profit vs Risk Rating (78) in the Biotechnology industry is in the same range as LSTA (100) in the null industry. This means that ASND’s stock grew similarly to LSTA’s over the last 12 months.

LSTA's SMR Rating (97) in the null industry is in the same range as ASND (100) in the Biotechnology industry. This means that LSTA’s stock grew similarly to ASND’s over the last 12 months.

ASND's Price Growth Rating (44) in the Biotechnology industry is in the same range as LSTA (53) in the null industry. This means that ASND’s stock grew similarly to LSTA’s over the last 12 months.

ASND's P/E Growth Rating (100) in the Biotechnology industry is in the same range as LSTA (100) in the null industry. This means that ASND’s stock grew similarly to LSTA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ASNDLSTA
RSI
ODDS (%)
Bearish Trend 4 days ago
76%
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
81%
Bullish Trend 4 days ago
79%
Momentum
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
80%
MACD
ODDS (%)
Bearish Trend 4 days ago
65%
Bullish Trend 4 days ago
72%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
74%
Bullish Trend 4 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
73%
Bullish Trend 4 days ago
80%
Advances
ODDS (%)
N/A
Bullish Trend 5 days ago
79%
Declines
ODDS (%)
Bearish Trend 4 days ago
77%
Bearish Trend 20 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
64%
Bearish Trend 4 days ago
88%
Aroon
ODDS (%)
Bullish Trend 4 days ago
79%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ASND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LSTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
RFI11.980.14
+1.18%
Cohen and Steers Total Return Realty Fund
EUM23.080.12
+0.54%
ProShares Short MSCI Emerging Markets
UJUN35.500.05
+0.13%
Innovator U.S. Equity Ultra BffrETF™-Jun
ITWO36.20-0.10
-0.28%
ProShares Russell 2000 High Income ETF
GLTR137.13-2.67
-1.91%
abrdn Physical PrecMtlBsk Shrs ETF

ASND and

Correlation & Price change

A.I.dvisor indicates that over the last year, ASND has been loosely correlated with NUVL. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ASND jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ASND
1D Price
Change %
ASND100%
-0.42%
NUVL - ASND
39%
Loosely correlated
+0.68%
ZNTL - ASND
35%
Loosely correlated
-6.35%
KYMR - ASND
32%
Poorly correlated
-3.48%
ZYME - ASND
32%
Poorly correlated
+0.81%
BMRN - ASND
31%
Poorly correlated
+1.98%
More

LSTA and

Correlation & Price change

A.I.dvisor tells us that LSTA and RAIN have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LSTA and RAIN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LSTA
1D Price
Change %
LSTA100%
-4.76%
RAIN - LSTA
27%
Poorly correlated
+5.79%
GMAB - LSTA
27%
Poorly correlated
-1.11%
IMVT - LSTA
27%
Poorly correlated
-1.77%
ASND - LSTA
26%
Poorly correlated
-0.42%
TPST - LSTA
26%
Poorly correlated
-2.68%
More